Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach | Zendy

John Moua | Zendy; Eliezer Nussbaum | Zendy; Eileen Liao | Zendy; Inderpal Randhawa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach

Author(s) -

John Moua,

Eliezer Nussbaum,

Eileen Liao,

Inderpal Randhawa

Publication year - 2013

Publication title -

therapeutic advances in respiratory disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.022

H-Index - 37

eISSN - 1753-4666

pISSN - 1753-4658

DOI - 10.1177/1753465813482744

Subject(s) - medicine , atenolol , adverse effect , cystic fibrosis , beta blocker , refractory (planetary science) , blockade , complication , anesthesia , surgery , blood pressure , heart failure , physics , receptor , astrobiology

/objective: Recurrent hemoptysis is a debilitating complication of cystic fibrosis (CF) and likely results from mucosal erosions into abnormal bronchial blood vessels due to chronic respiratory infection. We hypothesize that the use of beta-blockade will decrease mean arterial pressure resulting in lower bronchial artery blood flow and, subsequently, decrease the frequency and severity of hemoptysis, rate of hospitalizations, and usage of intravenous antibiotics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research